Health-related quality of life and quality-adjusted progression
By A Mystery Man Writer
Description
Background Decisions regarding maintenance therapy in patients with multiple myeloma should be based on both treatment efficacy and health-related quality of life (HRQL) consequences. In the CARFI trial, patients with first relapse of multiple myeloma underwent salvage autologous stem cell transplantation (salvage ASCT) before randomization to carfilzomib-dexamethasone maintenance therapy (Kd) or observation. The primary clinical endpoint was time to progression, which was extended by 8 months by Kd. The aim of this paper is to present the all HRQL endpoints of the CARFI trial including the HRQL effect of Kd maintenance therapy relative to observation. The primary HRQL endpoint was assessed by EORTC QLQ-C30 Summary score (QLQ-C30-sum) at 8 months follow-up. A key secondary HRQL endpoint was quality-adjusted progression-free-survival (QAPFS). Methods HRQL was assessed with EORTC QLQ-C30, EORTC QLQ-MY20 and FACT/GOG-Ntx at randomization and every second month during follow-up. HRQL data were analyzed with linear mixed effect models until 8 months follow-up. QAPFS per individual was calculated by multiplying progression-free survival (PFS) by two quality-adjustment metrics, the QLQ-C30-sum and EORTC Quality of Life Utility Measure-Core 10 dimensions (QLU-C10D). The QAPFS per treatment group was estimated with the Kaplan-Meier method. P < 0.05 was used for statistical significance, and a between-group minimal important difference of 10 points was interpreted as clinically relevant for the QLQ-C30-sum. Results 168 patients were randomized. HRQL questionnaire compliance was 93%. For the QLQ-C30-sum, the difference of 4.62 points (95% confidence interval (CI) -8.9: -0.4, p = 0.032) was not clinically relevant. PFS was 19.3 months for the Kd maintenance group and 16.8 months for the observation group; difference = 2.5 months (95% CI 0.5; 4.5). QAPFS based on the QLQ-C30-sum for the Kd maintenance group was 18.0 months (95% CI 16.4; 19.6) and for the observation group 15.0 months (95% CI 13.5; 16.5); difference = 3.0 months (95% CI 0.8–5.3). QAPFS based on the QLU-C10D for the Kd maintenance group was 17.5 months (95% CI 15.9; 19.2) and 14.0 months (95% CI 12.4; 15.5) for the observation group; difference = 3.5 months (95% CI 1.1–5.9). Conclusions Kd maintenance therapy after salvage ASCT did not adversely affect overall HRQL, but adjustment for HRQL reduced the PFS compared to unadjusted PFS. PFS of maintenance therapy should be quality-adjusted to balance the benefits and HRQL impact.
![Health-related quality of life and quality-adjusted progression](https://image.slidesharecdn.com/phrmaproject-onlineversion-160525105901/85/options-for-formulary-development-in-middleincome-countries-14-320.jpg?cb=1668241259)
OPTIONS FOR FORMULARY DEVELOPMENT IN MIDDLE-INCOME COUNTRIES
![Health-related quality of life and quality-adjusted progression](https://www.ous-research.no/myeloma/docs/image/OMC-gruppebilde-2023_web.jpg)
OUH - Oslo Myeloma Center
![Health-related quality of life and quality-adjusted progression](https://i1.rgstatic.net/publication/335380379_Estimation_of_minimally_important_differences_and_responder_definitions_for_EORTC_QLQ-MY20_scores_in_multiple_myeloma_patients/links/5ddea8664585159aa44e37e5/largepreview.png)
PDF) Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients
![Health-related quality of life and quality-adjusted progression](https://ous-research.no/wcache/100x_d59432ae36548e6036c598e54a27e0d1Iatimad_Timet_Oulkadi_web.jpg)
OUH - Group members
![Health-related quality of life and quality-adjusted progression](https://www.tandfonline.com/cms/asset/a3be9537-edc1-47ab-ad6f-d9ceaeaa45f3/iasl_a_1151935_f0001_b.jpg)
Full article: Contribution of speech and language difficulties to health-related quality-of-life in Australian children: A longitudinal analysis
![Health-related quality of life and quality-adjusted progression](https://communitycommons.s3.amazonaws.com/images/societal-value-vaccination-age-covid-19.png)
The Societal Value of Vaccination in the Age of COVID-19
![Health-related quality of life and quality-adjusted progression](https://www.researchgate.net/publication/364404755/figure/fig1/AS:11431281091313454@1666368270716/Type-of-graphs-used-in-FDA-labels-to-commnicate-PROs-A-Proportion-of-patients.png)
Type of graphs used in FDA labels to commnicate PROs. (A) Proportion of
![Health-related quality of life and quality-adjusted progression](https://upload.wikimedia.org/wikipedia/commons/thumb/5/59/QALY_graph-en.svg/640px-QALY_graph-en.svg.png)
Quality-adjusted life year - Wikipedia
Health-related quality of life change over time. Estimated change in
![Health-related quality of life and quality-adjusted progression](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41375-019-0480-2/MediaObjects/41375_2019_480_Fig1_HTML.png)
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
![Health-related quality of life and quality-adjusted progression](https://www.researchgate.net/publication/331289512/figure/tbl2/AS:730732779536384@1551231679698/Extent-of-missing-QLQ-C30-questionnaires-intention-to-treat.png)
Extent of missing QLQ-C30 questionnaires (intention-to-treat)
![Health-related quality of life and quality-adjusted progression](https://www.researchgate.net/publication/362824866/figure/fig1/AS:11431281080007242@1661013065703/Overview-of-item-development-process-QOL-quality-of-life-HRQOL-health-related-quality_Q320.jpg)
Overview of item development process. QOL, quality of life; HRQOL
![Health-related quality of life and quality-adjusted progression](https://www.researchgate.net/publication/377981241/figure/fig2/AS:11431281222387628@1707227981070/Quality-adjusted-progression-free-survival-based-on-the-EORTC-QLQ-C30-Summary-score-and_Q320.jpg)
Quality-adjusted progression-free-survival based on the EORTC QLQ-C30
![Health-related quality of life and quality-adjusted progression](https://i1.rgstatic.net/publication/326677471_Impact_of_post-transplantation_maintenance_therapy_on_health-related_quality_of_life_in_patients_with_multiple_myeloma_data_from_the_ConnectR_MM_Registry/links/5fb71b59458515b797558595/largepreview.png)
PDF) Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
![Health-related quality of life and quality-adjusted progression](https://www.researchgate.net/publication/343113435/figure/fig1/AS:958462418771975@1605526656246/CONSORT-diagram-AE-adverse-event-PBSC-peripheral-blood-stem-cell-HDCT-ASCT-high-dose.png)
CONSORT diagram AE adverse event, PBSC peripheral blood stem cell
from
per adult (price varies by group size)